Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
The phase 3 FLOW trial evaluated Ozempic in patients with T2DM and chronic kidney disease (CKD)
Both use the GLP-1 pathway to reduce appetite and support weight loss
While lightheadedness or dizziness is not listed among the most frequent side effects in the official product labeling, patients and healthcare providers have reported this symptom in clinical practice
Ozempic and Wegovy (and Rybelsus, which is oral semaglutide) are GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists, commonly referred to as GLP-1s) and are the only FDA-approved drugs that contain the active ingredient semaglutide
US$ 23.84
US$ 21.20
US$ 22.54
US$ 21.79
US$ 24.25
US$ 20.44
